Clinical Trial

Effect of Tezepelumab on Barrier Function in Severe Asthmatic Patients With and Without Comorbid Chronic Rhinosinusitis With Nasal Polyps

Study acronym: Tezebarrier
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
In this study, we will investigate the effect of tezepelumab on the epithelial barrier function of the upper and lower airways in patients suffering from severe asthma with and without chronic rhinosinusitis with nasal polyps. This will be achieved by analysis of epithelial barrier function upon challenge with various harmful substances (e.g. cigarette smoke extract, allergens) in cultured primary respiratory tract epithelial cells. Furthermore we will assess changes in clinical parameters, cellular composition and inflammatory mediators.
Trial Details
NCT Number NCT07046117
Lead Sponsor Medical University of Vienna
Conditions Asthma Bronchiale, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Enrollment 20 participants
Start Date 2025-10-01
Primary Completion 2028-01-31 (estimated)
Study Completion 2028-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-01